Novo Nordisk (NVO) Q3 2026 Earnings Call Transcript

Novo Nordisk reported Q3 2026 adjusted sales of DKK 79.2 billion, up 4% at constant exchange rates, and adjusted operating profit of DKK 32 billion, up 27%; management attributed profit growth partly to a favorable comparison with prior-year transformation costs. The company raised full-year 2026 guidance to -2% to +2% growth for both adjusted sales and adjusted operating profit, and forecast free cash flow of DKK 60 billion to DKK 70 billion. GLP-1 volume growth and Wegovy launches are supporting recovery, but U.S. price erosion, payer controls, and loss-of-exclusivity headwinds in Canada and China remain risks.

Analysis

The key underwriting issue is whether patient growth can outrun net-price compression—not whether launches are attracting prescriptions. The U.S. obesity category was described as broadly flat absent the Bridge contribution, making 2027 growth vulnerable as Bridge annualizes; commercial payer restrictions also cap the conversion of clinical demand into reimbursed volume. Meanwhile, steep Wegovy net-price erosion means share gains may carry weaker incremental revenue than headline prescription growth suggests. Treat NBRx share and pack counts as leading indicators, not proof of profitable expansion.

The pill can expand the treated population and complement injectables, but that benefit is conditional on retention, payer access, and economics. Faster international rollout increases reach while also exposing the franchise to markets where semaglutide exclusivity is ending and premium pricing may be harder to sustain. Near-term, the operating-profit comparison benefits from last year’s transformation-cost base; it should not be extrapolated as recurring leverage. The CagriSema head-to-head result is against a low tirzepatide dose, so it does not establish broad competitive superiority; the 2027 launch is a catalyst, while differentiation and adoption remain unproven.

Contrarian read: the recovery narrative may be underestimating the price/volume trade-off and the Bridge comp cliff, even as it overstates how much pill growth is merely cannibalization. Watch U.S. net sales per prescription, ex-Bridge category scripts, and international realized prices. A sustained rise in ex-Bridge volumes without worsening net price would falsify the cautious view; renewed payer restrictions or further price erosion would strengthen it.

Key Decisions for Investors

• Do not chase a post-results rally on patient adds or market share alone. Keep NVO exposure measured until the next quarter shows ex-Bridge U.S. prescription growth and stable net revenue per prescription; reassess if either deteriorates.
• For a 1–3 month catalyst stance, prefer a defined-risk, modest bearish NVO position only if the stock rallies on launch headlines without upward revenue guidance. Avoid setting a price target without current valuation and price data; exit the thesis if guidance improves on durable, non-Bridge volume rather than pricing or temporary access programs.
• Track 2027 launch economics, not launch counts: verify CagriSema approval/timing, payer coverage, early persistence, and realized price; monitor international Wegovy pill sales alongside semaglutide LOE markets. Treat CagriSema trial comparisons as dose-specific until broader head-to-head evidence is available.
• Falsification checklist: ex-Bridge U.S. category prescriptions turn sustainably positive; payer access broadens beyond temporary programs; realized pricing stabilizes; or guidance demonstrates that new products offset LOE and gross-to-net headwinds. Until then, no high-conviction directional trade is warranted.